Last Updated : August 3, 2022
Details
FilesGeneric Name:
Atezolizumab
Project Status:
Complete
Therapeutic Area:
Small Cell Lung Cancer (SCLC)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0156-000
NOC Status at Filing:
Pre NOC
Performance Metric:
N/A due to an external delay
Strength:
60 mg/mL
Tumour Type:
Lung
Indications:
Small Cell Lung Cancer (SCLC)
Funding Request:
For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity
Review Status:
Notification to Implement Issued
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Clarification:
A procedural review request has been received and granted.
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : August 3, 2022